Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Vera Therapeutics, a late-stage biotechnology company focused on immunological diseases, will present at the 13th Annual Wedbush PacGrow Healthcare Conference on August 10, 2022, from 12:00 – 12:30 PM ET. This virtual conference will also include one-on-one investor meetings. The company's lead product candidate, atacicept, targets autoimmune diseases like IgA nephropathy and lupus nephritis. A live audio webcast will be available, with a replay accessible for 90 days afterward. For more information, visit www.veratx.com.

BRISBANE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 13^th Annual Wedbush PacGrow Healthcare Conference, which is taking place virtually August 9-10, 2022. The Company will also participate in one-on-one investor meetings.

Presentation Details:

Date:	Wednesday, August 10, 2022
Time:	12:00 – 12:30 PM ET
Webcast:	A live audio webcast is available by choosing the following link https://bit.ly/3BAFobb

A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.

About Vera Therapeutics
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Kathy Vincent
Greig Communications, Inc.
kathy@greigcommunications.com

FAQ

When will Vera Therapeutics present at the Wedbush PacGrow Healthcare Conference?

Vera Therapeutics will present on August 10, 2022, from 12:00 to 12:30 PM ET.

How can I access the live webcast for Vera Therapeutics' presentation?

The live audio webcast can be accessed at this link: https://bit.ly/3BAFobb.

What is the purpose of Vera Therapeutics' participation in the conference?

Vera Therapeutics aims to showcase its developments in transformative treatments for serious immunological diseases.

What is atacicept, Vera Therapeutics' lead product candidate?

Atacicept is a fusion protein designed to treat autoimmune diseases by blocking specific proteins that stimulate B cells.

How long will the replay of the conference be available?

A replay of the presentation will be available for 90 days after the event.